Skip to content Adagene
Adagene Mobile Menu Toggle navigation
Adagene
  • DPL Platform
    • Dynamic Precision Library
    • NEObody
    • SAFEbody
    • POWERbody
  • Pipeline
    • Pipeline & Programs
    • ADG106
    • ADG126
    • ADG116
    • Publications
  • About
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Key Advisors
  • News & Events
  • Careers
  • Investors
  • Contact
  • Privacy
  • Terms of Use
  • DPL Platform
    • Dynamic Precision Library
    • NEObody
    • SAFEbody
    • POWERbody
  • Pipeline
    • Pipeline & Programs
    • ADG106
    • ADG126
    • ADG116
    • Publications
  • About
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Key Advisors
  • News & Events
  • Careers
  • Investors
  • Contact
  • Privacy
  • Terms of Use

Pipeline

Publications

Phase 1, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma
ADG106 | ASCO 2020

A Safe and Potent Agonist ADG106 Targeting a Unique Epitope of CD137 with Novel Mechanism of Actions
ADG106 | EORTC-NCI-AACR 2019

Development of a novel antagonist anti-CTLA-4 antibody for cancer immunotherapy
ADG116 | SITC 2019

© 2021 Adagene

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn